دورية أكاديمية
أعرض في EDS

Specificity Proteins (Sp) and Cancer.

التفاصيل البيبلوغرافية
العنوان: Specificity Proteins (Sp) and Cancer.
المؤلفون: Safe S; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 08; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 08.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , MicroRNAs*/genetics , Rhabdomyosarcoma*/genetics, Humans ; Sp Transcription Factors/metabolism ; Sp1 Transcription Factor/genetics ; Sp1 Transcription Factor/metabolism ; Sp3 Transcription Factor/metabolism ; Gene Expression Regulation, Neoplastic
مستخلص: The specificity protein (Sp) transcription factors (TFs) Sp1, Sp2, Sp3 and Sp4 exhibit structural and functional similarities in cancer cells and extensive studies of Sp1 show that it is a negative prognostic factor for patients with multiple tumor types. In this review, the role of Sp1, Sp3 and Sp4 in the development of cancer and their regulation of pro-oncogenic factors and pathways is reviewed. In addition, interactions with non-coding RNAs and the development of agents that target Sp transcription factors are also discussed. Studies on normal cell transformation into cancer cell lines show that this transformation process is accompanied by increased levels of Sp1 in most cell models, and in the transformation of muscle cells into rhabdomyosarcoma, both Sp1 and Sp3, but not Sp4, are increased. The pro-oncogenic functions of Sp1, Sp3 and Sp4 in cancer cell lines were studied in knockdown studies where silencing of each individual Sp TF decreased cancer growth, invasion and induced apoptosis. Silencing of an individual Sp TF was not compensated for by the other two and it was concluded that Sp1, Sp3 and Sp4 are examples of non-oncogene addicted genes. This conclusion was strengthened by the results of Sp TF interactions with non-coding microRNAs and long non-coding RNAs where Sp1 contributed to pro-oncogenic functions of Sp/non-coding RNAs. There are now many examples of anticancer agents and pharmaceuticals that induce downregulation/degradation of Sp1, Sp3 and Sp4, yet clinical applications of drugs specifically targeting Sp TFs are not being used. The application of agents targeting Sp TFs in combination therapies should be considered for their potential to enhance treatment efficacy and decrease toxic side effects.
References: IUBMB Life. 2020 Feb;72(2):237-246. (PMID: 31478331)
Cell Death Dis. 2012 Nov 29;3:e436. (PMID: 23190608)
PLoS One. 2014 Jun 24;9(6):e98651. (PMID: 24959930)
Mol Cell Biol. 2014 Jul;34(13):2382-95. (PMID: 24732804)
BMC Mol Biol. 2007 May 20;8:36. (PMID: 17511886)
Pharmacol Ther. 2015 Aug;152:111-24. (PMID: 25960131)
Kaohsiung J Med Sci. 2021 May;37(5):371-378. (PMID: 33089960)
Biochem Biophys Res Commun. 2020 Jun 4;526(3):670-677. (PMID: 32248969)
Mol Cell. 2011 Sep 16;43(6):904-14. (PMID: 21925379)
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8913-8920. (PMID: 31696478)
J Biol Chem. 2016 Dec 30;291(53):27122-27133. (PMID: 27875298)
Oncogene. 2012 Feb 23;31(8):1034-44. (PMID: 21765466)
Cell Signal. 2005 Feb;17(2):153-66. (PMID: 15494207)
Oncogene. 2012 Aug 30;31(35):3973-88. (PMID: 22158040)
Oncol Rep. 2014 Jan;31(1):117-24. (PMID: 24173369)
Mol Med Rep. 2023 Jan;27(1):. (PMID: 36453238)
Bioengineered. 2021 Dec;12(1):6305-6317. (PMID: 34499009)
J Biol Chem. 2014 Apr 18;289(16):11194-11205. (PMID: 24627491)
J Exp Clin Cancer Res. 2020 Jun 23;39(1):118. (PMID: 32576271)
Mol Cancer. 2011 Jan 09;10:4. (PMID: 21214951)
Cancer Sci. 2018 May;109(5):1346-1356. (PMID: 29575609)
Mol Cancer Res. 2011 Feb;9(2):195-202. (PMID: 21156786)
Biomed Pharmacother. 2019 Sep;117:109133. (PMID: 31252264)
Carcinogenesis. 2012 Apr;33(4):886-94. (PMID: 22334592)
Oncotarget. 2016 Dec 27;7(52):85905-85916. (PMID: 27829234)
Front Oncol. 2020 Mar 13;10:294. (PMID: 32231999)
J Natl Cancer Inst. 2006 Jun 21;98(12):855-68. (PMID: 16788159)
Cancer Lett. 2022 Mar 1;528:16-30. (PMID: 34958891)
PLoS One. 2016 Mar 16;11(3):e0151598. (PMID: 26981862)
Cell. 1983 Mar;32(3):669-80. (PMID: 6187469)
EMBO J. 1994 Aug 15;13(16):3843-51. (PMID: 8070411)
Cell Oncol (Dordr). 2013 Oct;36(5):385-94. (PMID: 23999873)
Cell Death Dis. 2021 May 1;12(5):437. (PMID: 33934099)
Oncotarget. 2016 Aug 30;7(35):56540-56557. (PMID: 27447744)
J Cell Physiol. 2020 Apr;235(4):3916-3927. (PMID: 31608997)
PLoS One. 2015 Jul 15;10(7):e0133074. (PMID: 26177288)
Oncotarget. 2016 Apr 19;7(16):22245-56. (PMID: 26967243)
Mol Cancer Res. 2017 Jun;15(6):776-785. (PMID: 28219935)
Genomics. 1995 Apr 10;26(3):631-3. (PMID: 7607696)
BMC Cancer. 2011 Aug 24;11:371. (PMID: 21864401)
Int J Oncol. 2014 Aug;45(2):667-74. (PMID: 24858379)
Cell Death Dis. 2020 Sep 11;11(9):743. (PMID: 32917852)
Mol Pharmacol. 2010 Aug;78(2):226-36. (PMID: 20488920)
Carcinogenesis. 2009 Jul;30(7):1125-31. (PMID: 19420015)
Int J Oncol. 2016 Jul;49(1):325-35. (PMID: 27212195)
Anticancer Drugs. 2019 Feb;30(2):153-158. (PMID: 30362980)
J Biol Chem. 2011 Dec 16;286(50):43091-102. (PMID: 22020934)
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):3906-11. (PMID: 21368148)
Biochem Pharmacol. 2001 Jul 1;62(1):51-62. (PMID: 11377396)
Int Urol Nephrol. 2022 Jul;54(7):1505-1512. (PMID: 35467245)
Adv Sci (Weinh). 2020 Mar 11;7(10):1903233. (PMID: 32440474)
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4109-17. (PMID: 15217947)
BMC Cancer. 2012 Nov 30;12:564. (PMID: 23194063)
Toxicol Appl Pharmacol. 2019 Sep 1;378:114606. (PMID: 31170415)
Nat Rev Mol Cell Biol. 2023 Jan 3;:. (PMID: 36596869)
Breast Cancer Res Treat. 2014 Oct;147(3):487-500. (PMID: 25193278)
Mol Cell Biol. 2016 Oct 13;36(21):2742-2754. (PMID: 27550813)
Cancers (Basel). 2020 Jul 27;12(8):. (PMID: 32726929)
Oncogene. 2012 Mar 15;31(11):1398-407. (PMID: 21822301)
Carcinogenesis. 2013 Dec;34(12):2870-9. (PMID: 23803693)
Epigenetics. 2023 Dec;18(1):2148433. (PMID: 36476264)
Cell Death Differ. 2022 Mar;29(3):627-641. (PMID: 34608273)
Noncoding RNA Res. 2016 Nov 12;1(1):43-50. (PMID: 30159410)
Signal Transduct Target Ther. 2022 Feb 21;7(1):49. (PMID: 35185151)
Exp Cell Res. 2010 Aug 1;316(13):2174-88. (PMID: 20435036)
Biol Res. 2018 Nov 24;51(1):51. (PMID: 30474556)
Gene. 2019 Apr 15;692:223-230. (PMID: 30659947)
Ai Zheng. 2007 Sep;26(9):996-1000. (PMID: 17927860)
Cancer Res. 2006 Feb 1;66(3):1277-81. (PMID: 16452179)
Biochem Biophys Res Commun. 2020 Dec 17;533(4):779-785. (PMID: 32988587)
Cancer Cell. 2011 Nov 15;20(5):606-19. (PMID: 22094255)
Mol Cancer Res. 2019 Mar;17(3):794-805. (PMID: 30610105)
Sci Rep. 2019 Apr 11;9(1):5933. (PMID: 30976063)
J Ethnopharmacol. 2019 Jun 12;237:128-140. (PMID: 30910577)
Nature. 1984 Nov 29-Dec 5;312(5993):409-13. (PMID: 6095100)
Biochem Biophys Res Commun. 2021 Jul 5;561:172-179. (PMID: 34023783)
Mol Cancer Ther. 2015 Sep;14(9):2143-53. (PMID: 26162688)
J BUON. 2020 Jan-Feb;25(1):344-349. (PMID: 32277653)
Dig Dis Sci. 2014 Aug;59(8):1743-53. (PMID: 24623314)
Int J Oncol. 2015 Jan;46(1):265-71. (PMID: 25310400)
World J Gastroenterol. 2005 Apr 21;11(15):2213-7. (PMID: 15818728)
FEBS Lett. 2014 Apr 2;588(7):1168-77. (PMID: 24613927)
Int J Mol Sci. 2019 Nov 11;20(22):. (PMID: 31717924)
PLoS One. 2012;7(9):e44917. (PMID: 23028678)
Clin Cancer Res. 2007 Feb 15;13(4):1123-32. (PMID: 17317820)
J Biol Chem. 1995 Oct 20;270(42):24989-94. (PMID: 7559627)
J Mol Biol. 2008 Jul 25;380(5):869-85. (PMID: 18572193)
Mol Carcinog. 2014 Feb;53 Suppl 1:E53-61. (PMID: 23670891)
Cell Death Dis. 2021 Aug 21;12(9):802. (PMID: 34420031)
Cancer Res. 2004 Mar 15;64(6):2030-8. (PMID: 15026340)
Adv Exp Med Biol. 2011;720:191-207. (PMID: 21901629)
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52. (PMID: 18628415)
Oncol Rep. 2016 Jul;36(1):487-93. (PMID: 27222350)
Pathol Res Pract. 2019 Jul;215(7):152446. (PMID: 31126819)
Cell. 2012 Apr 27;149(3):515-24. (PMID: 22541426)
Clin Cancer Res. 2013 May 1;19(9):2355-67. (PMID: 23493348)
J Biomed Sci. 2022 Jan 17;29(1):3. (PMID: 35034634)
RNA. 2014 Jan;20(1):61-75. (PMID: 24249224)
Oncol Rep. 2013 Jul;30(1):327-33. (PMID: 23670210)
Ann Anat. 2010 Sep 20;192(5):275-83. (PMID: 20810260)
J Cell Mol Med. 2019 Jun;23(6):4386-4394. (PMID: 30973678)
Oncogene. 2015 Nov 5;34(45):5648-61. (PMID: 25728677)
J Cancer. 2022 Jan 1;13(1):102-111. (PMID: 34976174)
Eur J Biochem. 1999 Apr;261(1):269-74. (PMID: 10103059)
Cancers (Basel). 2020 Apr 15;12(4):. (PMID: 32326583)
Phytother Res. 2016 Nov;30(11):1723-1732. (PMID: 27384261)
PLoS One. 2012;7(10):e48208. (PMID: 23110215)
Cancer Res. 2005 Feb 1;65(3):1007-17. (PMID: 15705902)
Cancer Cell Int. 2018 Oct 25;18:171. (PMID: 30386180)
Clin Cancer Res. 2013 Oct 15;19(20):5602-12. (PMID: 23995857)
J Pathol. 2013 Jan;229(1):12-24. (PMID: 22821729)
Int J Mol Sci. 2022 Sep 01;23(17):. (PMID: 36077352)
Nutr Cancer. 2011;63(7):1133-42. (PMID: 21919647)
Toxicol Sci. 2019 Jul 31;:. (PMID: 31368498)
Apoptosis. 2017 May;22(5):719-729. (PMID: 28283889)
Int J Mol Sci. 2022 Oct 04;23(19):. (PMID: 36233051)
Oncol Lett. 2019 Oct;18(4):4126-4135. (PMID: 31579418)
Pathol Oncol Res. 2019 Jul;25(3):1003-1013. (PMID: 29948615)
Int J Biochem Cell Biol. 2015 Jul;64:287-97. (PMID: 25982202)
Aging (Albany NY). 2019 Mar 10;11(5):1389-1403. (PMID: 30853664)
Cancer Sci. 2010 Jun;101(6):1463-70. (PMID: 20384626)
Hum Cell. 2021 May;34(3):952-964. (PMID: 33728585)
Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616)
Cell Death Dis. 2022 May 4;13(5):433. (PMID: 35508523)
Oral Oncol. 2014 Nov;50(11):1062-71. (PMID: 25127200)
Cancer Manag Res. 2021 Sep 21;13:7299-7309. (PMID: 34584456)
Oncogene. 2022 Jan;41(1):99-111. (PMID: 34697449)
Cancer Sci. 2022 Aug;113(8):2681-2692. (PMID: 35637600)
Mol Pharmacol. 2012 Dec;82(6):1115-28. (PMID: 22956772)
Cancer Cell. 2010 Apr 13;17(4):333-47. (PMID: 20385359)
Mol Cell. 2010 Oct 22;40(2):205-15. (PMID: 20965416)
Oncol Rep. 2015 Feb;33(2):631-8. (PMID: 25434704)
Cancer Biol Med. 2020 Nov 15;17(4):953-969. (PMID: 33299646)
PLoS One. 2009;4(2):e4478. (PMID: 19212434)
Int J Oncol. 2013 Oct;43(4):1103-10. (PMID: 23877711)
Cancer Lett. 2017 Nov 1;408:102-111. (PMID: 28844709)
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2205-2217. (PMID: 32196572)
Mol Carcinog. 2020 May;59(5):492-502. (PMID: 32128886)
Biomed Pharmacother. 2022 Feb;146:112442. (PMID: 35062053)
J Biol Chem. 2011 Jun 17;286(24):21401-12. (PMID: 21518763)
Cell Death Dis. 2018 Feb 6;9(2):157. (PMID: 29410403)
Anticancer Agents Med Chem. 2022;22(1):152-159. (PMID: 34225636)
Biochem Biophys Res Commun. 2016 Jan 1;469(1):87-93. (PMID: 26631963)
Front Endocrinol (Lausanne). 2022 Jul 26;13:936037. (PMID: 35957833)
Cancer Res. 2017 Aug 1;77(15):3965-3981. (PMID: 28701486)
PLoS One. 2013;8(2):e55522. (PMID: 23437057)
Biochem Biophys Res Commun. 2017 Nov 4;493(1):14-19. (PMID: 28939040)
Cancer Med. 2020 May;9(10):3592-3603. (PMID: 32160655)
Curr Pharmacol Rep. 2015 Apr;1(2):73-78. (PMID: 26457240)
Cancer Res. 2004 May 1;64(9):3072-8. (PMID: 15126343)
Tumour Biol. 2016 Oct;37(10):13287-13294. (PMID: 27460077)
Aging (Albany NY). 2020 Aug 28;12(16):16304-16325. (PMID: 32857725)
Tumour Biol. 2014 Oct;35(10):10019-23. (PMID: 25012245)
Mol Cell Biol. 1992 Oct;12(10):4251-61. (PMID: 1341900)
Cancer Res. 2007 Mar 15;67(6):2816-23. (PMID: 17363604)
J Ethnopharmacol. 2022 Jan 30;283:114456. (PMID: 34333105)
Int J Cancer. 2012 Feb 1;130(3):593-601. (PMID: 21469139)
Mol Cancer Ther. 2013 Nov;12(11):2483-93. (PMID: 24030632)
Mol Cancer Ther. 2012 Jul;11(7):1421-31. (PMID: 22553354)
Biochem Biophys Res Commun. 2020 Mar 26;524(1):211-216. (PMID: 31983431)
Neuro Oncol. 2014 Nov;16(11):1510-22. (PMID: 24951112)
Mol Pharmacol. 2018 Oct;94(4):1187-1196. (PMID: 30115673)
Gastroenterology. 2017 Jun;152(8):1845-1875. (PMID: 28366734)
FEBS J. 2015 Jan;282(2):224-58. (PMID: 25393971)
Aging (Albany NY). 2019 Sep 22;11(18):7357-7385. (PMID: 31543507)
Cell Cycle. 2020 Mar;19(6):711-725. (PMID: 32089063)
Mol Pharmacol. 2009 Jul;76(1):47-57. (PMID: 19372209)
PLoS One. 2018 Feb 1;13(2):e0192264. (PMID: 29389953)
Biochem Biophys Res Commun. 2021 Apr 23;550:113-119. (PMID: 33691197)
Mol Cancer Ther. 2017 Jan;16(1):205-216. (PMID: 27811009)
EMBO J. 2002 Oct 1;21(19):5206-15. (PMID: 12356736)
Oncol Lett. 2016 Jul;12(1):504-512. (PMID: 27347172)
Med Oncol. 2013 Jun;30(2):542. (PMID: 23529765)
Neuroreport. 2020 Jan 27;31(2):109-117. (PMID: 31876683)
Funct Integr Genomics. 2023 Jan 10;23(1):33. (PMID: 36625940)
Cancer Res. 2010 Nov 1;70(21):8507-16. (PMID: 20959487)
Pathol Oncol Res. 2021 Jan 28;27:581998. (PMID: 34257529)
Sci Rep. 2016 Aug 22;6:31804. (PMID: 27545642)
Int J Oncol. 2012 Jul;41(1):76-82. (PMID: 22552540)
Oncotarget. 2016 Nov 29;7(48):78557-78565. (PMID: 27713167)
Front Biosci (Schol Ed). 2011 Jan 01;3(2):797-805. (PMID: 21196413)
Mol Cancer Ther. 2016 Mar;15(3):512-22. (PMID: 26832795)
Apoptosis. 2018 Jan;23(1):65-78. (PMID: 29236199)
Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L983-92. (PMID: 16815888)
Clin Cancer Res. 2003 Dec 15;9(17):6371-80. (PMID: 14695137)
Cell Oncol (Dordr). 2021 Feb;44(1):61-76. (PMID: 32488851)
Oncotarget. 2016 May 10;7(19):27975-87. (PMID: 27057625)
Biomed Res Int. 2020 Aug 10;2020:1358674. (PMID: 32851058)
J Biol Chem. 2010 Aug 13;285(33):25332-44. (PMID: 20538607)
Oncogene. 2022 Jun;41(23):3222-3238. (PMID: 35508543)
J Biol Chem. 2014 Oct 3;289(40):27692-701. (PMID: 25143389)
Clin Sci (Lond). 2020 Nov 27;134(22):3007-3022. (PMID: 33103728)
Int Immunopharmacol. 2021 Sep;98:107858. (PMID: 34147913)
Genomics. 1996 Nov 1;37(3):410-2. (PMID: 8938460)
Mol Cell Probes. 2019 Aug;46:101417. (PMID: 31254619)
Am J Pathol. 2011 Nov;179(5):2580-8. (PMID: 21945323)
Mol Oncol. 2020 Oct;14(10):2678-2695. (PMID: 32634265)
Blood Cancer J. 2016 Jan 15;6:e380. (PMID: 26771806)
Int J Cancer. 2013 Feb 15;132(4):795-806. (PMID: 22815231)
Cancer Prev Res (Phila). 2018 Jul;11(7):371-382. (PMID: 29545399)
PLoS One. 2017 Feb 13;12(2):e0171827. (PMID: 28192510)
Cancer Prev Res (Phila). 2017 Aug;10(8):467-477. (PMID: 28673967)
Oncol Lett. 2016 Oct;12(4):2906-2911. (PMID: 27698878)
Anticancer Drugs. 2022 Feb 1;33(2):178-190. (PMID: 34620745)
N Engl J Med. 2018 Jul 12;379(2):122-137. (PMID: 29863451)
Nat Cell Biol. 2019 May;21(5):542-551. (PMID: 31048766)
J Biol Chem. 2013 Nov 22;288(47):33927-33938. (PMID: 24129563)
Drug Dev Res. 2015 Feb;76(1):9-16. (PMID: 25619802)
Cancer Res. 2008 Dec 1;68(23):9583-8. (PMID: 19047133)
J Mol Biol. 2011 Nov 18;414(1):1-14. (PMID: 21983342)
Mol Cell Biol. 1997 Nov;17(11):6348-58. (PMID: 9343396)
Onco Targets Ther. 2022 Mar 09;15:219-235. (PMID: 35299997)
Neoplasma. 2022 Jul;69(4):918-930. (PMID: 35652619)
معلومات مُعتمدة: P30 ES029067 United States ES NIEHS NIH HHS; P30-ES029067 United States NH NIH HHS
فهرسة مساهمة: Keywords: Sp1; Sp3; Sp4; non-oncogene addiction; pro-oncogenic; prognostic
المشرفين على المادة: 0 (Sp Transcription Factors)
0 (Antineoplastic Agents)
0 (MicroRNAs)
0 (Sp1 Transcription Factor)
148710-94-5 (Sp3 Transcription Factor)
تواريخ الأحداث: Date Created: 20230329 Date Completed: 20230330 Latest Revision: 20231130
رمز التحديث: 20231130
مُعرف محوري في PubMed: PMC10048989
DOI: 10.3390/ijms24065164
PMID: 36982239
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24065164